Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma

Rodabe N Amaria¹, Sangeetha M Reddy², Hussein A Tawbi¹, Michael A Davies¹, Merrick I Ross³, Isabella C Glitza¹, Janice N Cormier³, Carol Lewis⁴, Wen-Jen Hwu¹, Ehab Hanna⁴, Adi Diab¹, Michael K Wong¹, Richard Royal³, Neil Gross⁴, Randal Weber⁴, Stephen Y Lai⁴, Richard Ehlers³, Jorge Blando⁵, Denái R Milton⁶, Scott Woodman¹, Robin Kageyama⁷, Daniel K Wells⁷, Patrick Hwu¹, Sapna P Patel¹, Anthony Lucci³, Amy Hessel⁴, Jeffrey E Lee³, Jeffrey Gershenwald³, Lauren Simpson¹, Elizabeth M Burton³, Liberty Posada¹, Lauren Haydu³, Linghua Wang⁸, Shaojun Zhang⁸, Alexander J Lazar⁹, Courtney W Hudgens⁹, Vancheswaran Gopalakrishnan³, Alexandre Reuben³, Miles C Andrews³, Christine N Spencer⁸, Victor Prieto⁹, Padmanee Sharma^{5

10}, James Allison⁵, Michael T Tetzlaff^{9

11}, Jennifer A Wargo^{12

13}

Affiliations

¹ Department of Melanoma Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA.
² Department of Breast Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA.
³ Department of Surgical Oncology, MD Anderson Cancer Center, Houston, TX, USA.
⁴ Department of Head and Neck Surgery, MD Anderson Cancer Center, Houston, TX, USA.
⁵ Department of Immunology, MD Anderson Cancer Center, Houston, TX, USA.
⁶ Department of Biostatistics, MD Anderson Cancer Center, Houston, TX, USA.
⁷ Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA.
⁸ Department of Genomic Medicine, MD Anderson Cancer Center, Houston, TX, USA.
⁹ Department of Pathology, MD Anderson Cancer Center, Houston, TX, USA.
¹⁰ Department of Genitourinary Cancers, MD Anderson Cancer Center, Houston, TX, USA.
¹¹ Department of Translational and Molecular Pathology, MD Anderson Cancer Center, Houston, TX, USA.
¹² Department of Surgical Oncology, MD Anderson Cancer Center, Houston, TX, USA. jwargo@mdanderson.org.
¹³ Department of Genomic Medicine, MD Anderson Cancer Center, Houston, TX, USA. jwargo@mdanderson.org.

PMID: 30361511
DOI: 10.1038/s41591-018-0252-y

Published Erratum

Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma

Rodabe N Amaria et al. Nat Med. 2018 Dec.

. 2018 Dec;24(12):1942.

doi: 10.1038/s41591-018-0252-y.

Authors

Affiliations

¹ Department of Melanoma Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA.
² Department of Breast Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA.
³ Department of Surgical Oncology, MD Anderson Cancer Center, Houston, TX, USA.
⁴ Department of Head and Neck Surgery, MD Anderson Cancer Center, Houston, TX, USA.
⁵ Department of Immunology, MD Anderson Cancer Center, Houston, TX, USA.
⁶ Department of Biostatistics, MD Anderson Cancer Center, Houston, TX, USA.
⁷ Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA.
⁸ Department of Genomic Medicine, MD Anderson Cancer Center, Houston, TX, USA.
⁹ Department of Pathology, MD Anderson Cancer Center, Houston, TX, USA.
¹⁰ Department of Genitourinary Cancers, MD Anderson Cancer Center, Houston, TX, USA.
¹¹ Department of Translational and Molecular Pathology, MD Anderson Cancer Center, Houston, TX, USA.
¹² Department of Surgical Oncology, MD Anderson Cancer Center, Houston, TX, USA. jwargo@mdanderson.org.
¹³ Department of Genomic Medicine, MD Anderson Cancer Center, Houston, TX, USA. jwargo@mdanderson.org.

PMID: 30361511
DOI: 10.1038/s41591-018-0252-y

Abstract

In the version of this article originally published, there was an error in Fig. 1. In the neoadjuvant phase column, the n values for arms A and B were both reported to be 20. The n values for arms A and B were actually 12 and 11, respectively. Also, the URL underlying the accession code in the data availability section was incorrect. The URL was originally https://www.ebi.ac.uk/ega/studies/EGAS00001002698. It should have been https://www.ebi.ac.uk/ega/studies/EGAS00001003178. The errors have been corrected in the print, HTML and PDF versions of this article.

PubMed Disclaimer

Erratum for

Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.
Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA. Amaria RN, et al. Nat Med. 2018 Nov;24(11):1649-1654. doi: 10.1038/s41591-018-0197-1. Epub 2018 Oct 8. Nat Med. 2018. PMID: 30297909 Free PMC article. Clinical Trial.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma

Affiliations

Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma

Authors

Affiliations

Abstract

Erratum for

Publication types

LinkOut - more resources

Full Text Sources